AmnioStem LLC

AmnioStem LLC is a wholly owned subsidiary of Creative Medical Technology focused on developing therapeutic products derived from amniotic fluid stem cells. The company's core platform, AmnioStem, is described as a universal donor stem cell technology licensed from the University of California San Diego and is being explored primarily for regenerative medicine applications. Public disclosures indicate a lead preclinical focus in stroke, where the therapy has shown anti-inflammatory and neuroregenerative activity in laboratory and animal studies. The platform has also been discussed in preclinical work or patent-focused announcements for glioma, radiation toxicity, cachexia, and anti-aging applications. AmnioStem appears to function as a development subsidiary and platform vehicle rather than a broadly commercialized standalone operating company.